When I first coordinated a home trial visit for a patient with a rare metabolic disorder watching
a trained research nurse arrive at a family’s door in a Gulf city, cold chain supplies and protocol
checklist in hand, I realized we were witnessing a genuine paradigm shift. Not just in how trials
are run, but in what clinical research can mean for patients who have historically been the
furthest from it.
Decentralized clinical trials (DCTs) defined by the FDA’s 2023 guidance as trials “where some
or all trial-related activities occur at locations other than traditional clinical trial sites”, are
reshaping global research. The global DCT market was valued at approximately USD 8.8
billion in 2025 and is projected to reach USD 18.8 billion by 2030, growing at a compound
annual growth rate of 13.7%. In MENA specifically, the clinical trial infrastructure market is
expected to reach USD 1.3 billion by 2029, growing at a CAGR of 6.2%.
For those of us operating across Saudi Arabia, Qatar, UAE, Egypt, Lebanon, and Tunisia, these
numbers tell only part of the story. The real narrative is written in the operational trenches in
licensing calls with healthcare authorities, in cold chain planning for sub-Saharan heat, and in
the quiet triumph of completing a home visit for a child who cannot easily travel.
Here is what I have learned.
Why MENA Is a Compelling DCT Frontier
- An Extraordinary Rare Disease Burden
The MENA region is not only a growing market but also a scientifically unique one. High
consanguinity rates, large family sizes, and distinct population genetics have created one of the
world’s highest burdens of rare inherited disorders, presenting significant opportunities for rare
disease research and clinical trial recruitment.
However, many patients still experience delayed diagnosis, limited access to innovative
therapies, and underrepresentation in global clinical trials. Decentralized Clinical Trial (DCT)
models, through home healthcare, remote monitoring, and direct-to-patient logistics, can help
bridge this gap by bringing research directly to patients and expanding access to clinical studies
across the region.
- Ambitious National Health Agendas
Healthcare transformation across the MENA region is creating a more favorable environment
for clinical research. Saudi Arabia, the UAE, Qatar, and Egypt have modernized their
regulatory frameworks, strengthened clinical trial oversight, and invested in digital
infrastructure to attract international studies and generate region-specific evidence. Together,
these initiatives are positioning MENA as an increasingly important destination for global
clinical trials, particularly in areas of high unmet medical need such as rare and genetic
diseases.
- A Technology-Ready Population
MENA has some of the world’s highest smartphone penetration rates and strong urban digital
connectivity, particularly in the Gulf states. Younger populations who constitute a demographic
majority in many MENA countries are often highly receptive to telemedicine, ePRO tools, and
digital health platforms. This matters enormously for DCT elements such as e-consent, remote
monitoring, and virtual investigator contacts.
- Untapped Patient Populations for Global Trial Diversity
International regulatory agencies, including the FDA and EMA, increasingly emphasize the
need for ethnically and geographically diverse trial populations. MENA populations remain
profoundly underrepresented in global clinical evidence bases. Incorporating MENA sites
particularly through hybrid and decentralized models simultaneously addresses scientific
generalizability and ethical equity in trial access.
Key Challenges to Decentralized Clinical Trials in MENA
Despite significant progress, several barriers continue to affect DCT implementation across the
MENA region:
- Regulatory fragmentation: Each country has its own regulatory and ethics requirements, and
guidance for DCT-specific activities such as home visits, telemedicine, and direct-to-patient
IMP delivery remains limited in many jurisdictions.
- Home healthcare licensing: Licensing and sponsorship requirements for home healthcare
professionals vary between countries, making the deployment of GCP-trained nurses a
regulatory as well as an operational challenge that can delay study start-up.
- IMP logistics and cold chain: Cross-border importation, customs procedures, extreme
temperatures, and last-mile delivery require robust logistics planning to maintain investigational
product integrity and patient safety.
- Training and GCP competency: Home healthcare personnel require specialized training in
GCP, protocol compliance, safety reporting, specimen handling, and communication with
investigators to ensure high-quality trial conduct.
- Cultural considerations: Family-centered care, gender preferences, religious practices,
caregiver involvement, and varying health literacy levels should be incorporated into DCT
design to improve patient acceptance and retention.
- Digital infrastructure variability: Although Gulf countries have advanced digital health
capabilities, connectivity, device availability, and digital literacy vary across the region,
requiring flexible and patient-centered technology strategies.
What a Maturing MENA DCT Ecosystem Looks Like
A sustainable DCT ecosystem in MENA will be built on five key pillars:
Early regulatory engagement: Collaborate with health authorities and ethics committees
during protocol development to align on the oversight of home visits, telemedicine, and other
decentralized activities.
Qualified vendor networks: Establish robust ecosystems of GCP-trained home healthcare
providers, logistics partners, and service vendors through rigorous qualification and compliance
processes.
Hybrid trial models: Combine site-based visits for complex assessments with home-based
visits for routine monitoring, sample collection, and patient support to balance operational
efficiency with regulatory compliance.
Focus on rare diseases: Leverage the region’s high prevalence of inherited disorders to
improve patient access and accelerate recruitment through decentralized and hybrid trial
approaches.
Workforce development: Invest in accredited, region-specific training programs that equip
healthcare professionals with the clinical, regulatory, and operational skills required for
decentralized trial delivery.
The Path Forward: Three Priorities for MENA
- Promote Regulatory Harmonization
Greater alignment of regulatory expectations across MENA countries would facilitate multi-
country decentralized trials.
- Advance Inclusive Digital Infrastructure
Successful DCTs require digital solutions that are accessible to all patients. Platforms should
accommodate varying levels of connectivity and digital literacy to ensure equitable
participation across both urban and underserved communities.
- Strengthen Local DCT Ecosystems
Long-term success depends on building strong regional capabilities. Collaboration between
global sponsors and local CROs, home healthcare providers, logistics partners, and healthcare
institutions is essential to deliver culturally appropriate, compliant, and sustainable
decentralized trial services across MENA.
MENA has the advantage of stronger infrastructure and higher digital penetration, but the
lesson holds: DCT success requires building from the ground up, not bolting technology
onto outdated processes.
The infrastructure is being built. The regulations are evolving. The patient populations are
waiting. The question isn’t whether DCTs will transform clinical trials in MENA. It’s whether
MENA’s stakeholders will move fast enough to shape that transformation, or simply react to it.
What’s your experience with DCT implementation in MENA? I’d welcome perspectives from
sponsors, CROs, site investigators, and regulators in the comments.
References
- U.S. Food and Drug Administration. Decentralized clinical trials for drugs, biological products,
and devices: guidance for industry, investigators, and other stakeholders [Internet]. Silver
Spring (MD): FDA; 2023 May. Available from: https://www.fda.gov/media/167696/download
- European Medicines Agency. Reflection paper on decentralized elements in clinical trials.
EMA/599951/2021 [Internet]. Amsterdam: EMA; 2022 Mar. Available from:
https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-decentralised-
elements-clinical-trials_en.pdf
- Aamer W, Al-Maraghi A, Syed N, et al. Burden of Mendelian disorders in a large Middle
Eastern biobank. Genome Med. 2024;16:46.
- Al-Qahtani M, Al-Shammari A, Al-Otaibi S, et al. Towards a sustainable rare disease and
orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop.
Front Pharmacol. 2025;16:1583477.
- Gupta V, Sethuraman M, Bhatt D, et al. Home nursing in clinical trials: results from semi-
structured qualitative interviews. Perspect Clin Res. 2024;15(2):61–67.
- Nebie EI, Sawadogo HN, van Eeuwijk P, et al. Opportunities and challenges for decentralised
clinical trials in sub-Saharan Africa: a qualitative study. BMJ Open. 2023;13:e075903.
- Bower P, Brueton V, Gamble C, et al. Opportunities and counterintuitive challenges for
decentralized clinical trials to broaden participant inclusion. NPJ Digit Med. 2022;5:119.
- Menon S, Bhatt DL, Bhatt M, et al. Decentralized clinical trials—balancing promise and pitfalls
in modern research: a systematic review. Int J Clin Trials. 2024;11(3):205–214.
- International Council for Harmonisation (ICH). ICH Harmonised Guideline E6(R3): Good
Clinical Practice—Principles and Annex 1. Geneva: ICH; 2025.
